The name is a stack, not a molecule
EloraTZP is not a new peptide. It is Lilly’s label for eloralintide given together with tirzepatide: a selective amylin receptor agonist stacked on a dual GIP and GLP-1 receptor agonist. In the phase 2b study the two drugs were separate once-weekly injections. The product Lilly says it will take into phase 3 is a co-formulation — one syringe, two molecules, each keeping its own pharmacokinetics.
That design is the point. Amycretin welds GLP-1 and amylin into one chain and fixes the ratio. CagriSema is two pens of cagrilintide plus semaglutide. EloraTZP is the third answer: two satiety families, independently engineered, mixed rather than fused. A two-week amylin analog and a five-day dual incretin in the same injection is a mixture, not a molecule.
The 23% headline is not “amylin beat tirzepatide.” It is tirzepatide plus a second receptor family, in the harder population — obesity with type 2 diabetes — where every class loses less weight.
What the 48-week readout actually said
Lilly randomised 367 adults with obesity and type 2 diabetes across ten arms for 48 weeks and reported at EASD in Milan on 30 September 2026. It is a press release and a conference presentation; the paper has not been published (Lilly, 30 September 2026, PR Newswire, NCT06603571). Combination arms started at eloralintide 1 or 3 mg plus tirzepatide 2.5 mg and escalated every four weeks to target.
- The headline. Eloralintide 9 mg plus tirzepatide 15 mg: −23.3% body weight (~54.1 lb) and −2.9 A1C points. Tirzepatide 15 mg alone: −14.8% and −2.4. Eloralintide 6 mg plus tirzepatide 10 mg: −19.9%. Placebo: −3.0%.
- Eloralintide alone, this population. In people with type 2 diabetes, weekly eloralintide reached −8.2% at 3 mg, −12.3% at 6 mg, −11.1% at 9 mg. That is not the 20% from the obesity-without-diabetes monotherapy trial (The Lancet, December 2025; PMID 41207310). Diabetes is the harder room.
- The arithmetic. The top combination beat tirzepatide 15 mg by 8.5 points of weight. Eloralintide alone contributed about 11 to 12 points here. Less than fully additive — two satiety signals converging on overlapping hindbrain circuits would predict that — and still the largest number reported in this population to date. Do not rank it against retatrutide: there is no head-to-head.
- The cost. Discontinuation for adverse events ran 10.8% to 27.0% on combination arms, against 2.9% on tirzepatide alone and 0% to 10.8% on eloralintide alone. Gastrointestinal events were more frequent on the stack. Lilly attributes this to escalation and promises an optimised schedule for phase 3.
- The odd placebo. Placebo discontinuation was 16.7%, higher than most active arms, and placebo weight loss was 3.0%. Neither is explained in the release.
The 20% monotherapy figure that gets compared in passing is a different trial, a different population, and a published paper (PMID 41207310). EloraTZP’s 23.3% is still a release.
Three ways to put amylin next to an incretin
The field is not short of combination ideas. It is short of a ranking among them.
- CagriSema — two pens. Cagrilintide (dual amylin and calcitonin receptor agonist) plus semaglutide. Ratio can, in principle, be tuned. Two injections, two manufacturing paths.
- Amycretin — one chain. GLP-1 and amylin agonism welded into a single peptide. One pharmacokinetic profile, one titration — and a GLP-1-to-amylin ratio that cannot be dialled.
- EloraTZP — one syringe, two molecules. Selective amylin agonist plus tirzepatide (GIP/GLP-1). Co-formulation keeps each half-life; phase 2b still used two pens. The incretin half is already the dual agonist, not semaglutide.
Eloralintide’s monotherapy case — 20% at 48 weeks with no GLP-1 receptor in the molecule — is told in The note without the incretin. This page is the stack: whether that amylin note is worth adding to the best incretin Lilly already sells.
What phase 3 has to survive
Lilly says phase 3 of a co-formulated EloraTZP begins in Q4 2026. Until those trials enroll, report, and publish, the honest label is a conference topline in 367 people.
- Tolerability at scale. A 27% discontinuation arm is not a rounding error. An 'optimised escalation' is a hypothesis, not a result.
- The paper. Estimands, missing-data handling, which arm hit 27%, and whether the 8.5-point gap survives the primary analysis — none of that is in a press release.
- Co-formulation is not two pens. Phase 2b mixed two injections. Phase 3 of one product has to show the mixture still behaves when the two peptides share a vial.
- No league table. 23.3% in type 2 diabetes is not a ranking against retatrutide, CagriSema, or amycretin. Different populations, different durations, no shared control.
EloraTZP has shown that stacking a selective amylin agonist on tirzepatide can move weight and A1C past tirzepatide 15 mg in type 2 diabetes. It has not shown that the stack is livable, publishable, or better than the other two ways of putting amylin next to an incretin.
Common questions
- What is EloraTZP?
- EloraTZP is Eli Lilly's investigational combination of eloralintide, a once-weekly selective amylin receptor agonist, and tirzepatide, a dual GIP and GLP-1 receptor agonist (the active ingredient in Mounjaro and Zepbound). In the phase 2b trial the two drugs were given as separate weekly injections; Lilly plans phase 3 of a single co-formulated product by the end of 2026. Neither the combination nor eloralintide is approved.
- How much weight did people lose on EloraTZP vs tirzepatide?
- In a 48-week phase 2b trial of 367 adults with obesity and type 2 diabetes, reported at EASD on 30 September 2026, eloralintide 9 mg plus tirzepatide 15 mg produced a mean 23.3% weight loss (about 54.1 lb) and a 2.9-point A1C reduction, versus 14.8% and 2.4 points on tirzepatide 15 mg alone. Eloralintide 6 mg plus tirzepatide 10 mg reached 19.9%. Eloralintide alone in this diabetic population reached at most 12.3% (6 mg). The result is a sponsor release and conference presentation; the paper has not been published.
- When does EloraTZP enter phase 3?
- Lilly said, based on this 48-week phase 2b, it will initiate phase 3 trials of an EloraTZP co-formulation in Q4 2026, using an optimized escalation schedule. Eloralintide monotherapy is already in phase 3 for obesity (the ENLIGHTEN program). A press-release timeline is not enrollment; check ClinicalTrials.gov for the combination studies when they post.
- Is EloraTZP the same as CagriSema or amycretin?
- No. CagriSema is Novo's two-pen stack of cagrilintide (a dual amylin/calcitonin agonist) plus semaglutide. Amycretin is Novo's unimolecular GLP-1-plus-amylin peptide. EloraTZP is Lilly's two-molecule stack of a selective amylin agonist plus tirzepatide (GIP/GLP-1), intended as one co-formulated injection. Three answers to the same question — two satiety families — with different chemistry, different incretin half, and no head-to-head.
- Why did so many people discontinue EloraTZP?
- Treatment discontinuation for adverse events was 10.8% to 27.0% across EloraTZP arms, versus 2.9% on tirzepatide 15 mg, 0% to 10.8% on eloralintide alone, and 16.7% on placebo. Gastrointestinal events were the most common and were more frequent on the combination. The release attributes this to the escalation used in the trial and promises a different schedule for phase 3. A 27% arm is the number to watch when the paper appears; placebo discontinuation being higher than most active arms is unexplained in the release.
Keep going
- The note without the incretin — eloralintide alone
- Eloralintide — the catalog entry
- Tirzepatide — the incretin half
- Why tirzepatide isn't two drugs in one
- Amycretin — the unimolecular rival
- Eloralintide vs tirzepatide, side by side
- The GLP-3 bull case — the other large number
- Ask the research agent about EloraTZP
Educational reference on mechanism, summarized from public scientific literature and clinical-trial disclosures and simplified in places. Not individualized medical advice or a prescription. Where a dose or regimen appears it is reported from its source as research literacy — so you can read the evidence yourself — not an instruction to dose. Investigational, not approved: eloralintide and EloraTZP. Approved in the United States: tirzepatide. Status checked November 2026. Specific compounds and trials are named to explain the science; verify any claim against the linked primary sources.